![]() |
|
|
Vol. 288, Issue 1, 179-187, January 1999
Department of Pharmacology, The pharmacokinetics and pharmacodynamics of methadone were
investigated in control and abstinent rats. Minipumps filled with saline (control group) or saline-morphine (abstinent group) solutions were used to induce physical dependence. Solutions were delivered continuously by minipumps for 6 days. The physical dependence was
evaluated 12 h after minipump removal by measuring specific withdrawal signs. Animals from the abstinent group showed clear withdrawal signs such as hostility on handling and weight loss. Plasma
and brain disposition and pharmacodynamics of methadone were evaluated
after a 0.35 mg/kg i.v. bolus dose administered 12 h after
minipump removal. Plasma clearance, distribution clearance, and volume
of distribution at steady-state were significantly decreased
(P < 0.05) in the abstinent group. Plasma levels
of
1-acid glycoprotein and plasma protein binding were
significantly increased (P < 0.05) in the
abstinent group. The estimates of pharmacokinetic parameters based on
unbound plasma concentrations did not differ between groups, with the
sole exception of the unbound apparent volume of distribution. The
access of methadone to the brain was significantly faster
(P < 0.05) in the abstinent group, although the
extent of distribution in the brain was diminished in comparison with
the control group. Analgesia recorded with tail-flick was used as the
pharmacodynamic endpoint. Analgesic response and effect compartment
concentrations of methadone were related by the sigmoidal
Emax model. Estimates of
C50 [steady-state plasma concentrations
eliciting half of maximum effect (Emax)]] based on unbound concentrations did not differ between groups. On the
other hand, the estimate of Emax had
decreased by 65% in the abstinent group.
0022-3565/99/2881-0179$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
J. K. Melichar, S. P. Hume, T. M. Williams, M. R. C. Daglish, L. G. Taylor, R. Ahmad, A. L. Malizia, D. J. Brooks, J. S. Myles, A. Lingford-Hughes, et al. Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 309 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Valenzano, W. Miller, Z. Chen, S. Shan, G. Crumley, S. F. Victory, E. Davies, J.-C. Huang, N. Allie, S. J. Nolan, et al. DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 783 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Valle, M. J. Garrido, J. M. Pavón, R. Calvo, and I. F. Trocóniz Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)-O-Desmethyltramadol and (-)-O-Desmethyltramadol, in Rats J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 646 - 653. [Abstract] [Full Text] |
||||
![]() |
I. Echevarría, C. Barturen, M. J. Renedo, I. F. Trocóniz, and M. C. Dios-Viéitez Comparative Pharmacokinetics, Tissue Distributions, and Effects on Renal Function of Novel Polymeric Formulations of Amphotericin B and Amphotericin B-Deoxycholate in Rats Antimicrob. Agents Chemother., April 1, 2000; 44(4): 898 - 904. [Abstract] [Full Text] |
||||